The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.

about

The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.

Item

http://www.wikidata.org/entity/Q38577849

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The Central Role for Microenvi ...... ting and Anti-CD20 Antibodies.

@en

type

Item

label

The Central Role for Microenvi ...... ting and Anti-CD20 Antibodies.

@en

prefLabel

The Central Role for Microenvi ...... ting and Anti-CD20 Antibodies.

@en

P1476

The Central Role for Microenvi ...... ting and Anti-CD20 Antibodies.

@en

P2093

Nasser Pouladi

http://www.w3.org/2001/XMLSchema#string

Roghaye Tofigh

http://www.w3.org/2001/XMLSchema#string

Vahideh Ahmadzadeh

http://www.w3.org/2001/XMLSchema#string

P2860

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47

Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

CD20 deficiency in humans results in impaired T cell-independent antibody responses

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs

Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance

B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells

A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.

P304

136-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/08830185.2015.1077830

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Safar Farajnia

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26325124

http://www.w3.org/2001/XMLSchema#string